Financial Comparison: DXP Enterprises (NASDAQ:DXPE) versus Capstone Therapeutics (NASDAQ:CAPS)

Capstone Therapeutics (NASDAQ:CAPS) and DXP Enterprises (NASDAQ:DXPE) are both industrials companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, risk, valuation, analyst recommendations, dividends, earnings and profitability.

Institutional and Insider Ownership

2.5% of Capstone Therapeutics shares are held by institutional investors. Comparatively, 74.8% of DXP Enterprises shares are held by institutional investors. 39.3% of Capstone Therapeutics shares are held by insiders. Comparatively, 22.0% of DXP Enterprises shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Capstone Therapeutics and DXP Enterprises’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Capstone Therapeutics	-36.51%	-144.43%	-40.48%
DXP Enterprises	4.45%	18.67%	5.66%

Valuation and Earnings

This table compares Capstone Therapeutics and DXP Enterprises”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Capstone Therapeutics	$60.25 million	0.03	-$21.23 million	($100.60)	-0.02
DXP Enterprises	$2.02 billion	1.20	$88.68 million	$6.01	25.86

DXP Enterprises has higher revenue and earnings than Capstone Therapeutics. Capstone Therapeutics is trading at a lower price-to-earnings ratio than DXP Enterprises, indicating that it is currently the more affordable of the two stocks.

Volatility & Risk

Capstone Therapeutics has a beta of -1.35, suggesting that its stock price is 235% less volatile than the S&P 500. Comparatively, DXP Enterprises has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and recommmendations for Capstone Therapeutics and DXP Enterprises, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Capstone Therapeutics	1	0	0	0	1.00
DXP Enterprises	0	2	3	0	2.60

DXP Enterprises has a consensus price target of $183.00, indicating a potential upside of 17.76%. Given DXP Enterprises’ stronger consensus rating and higher possible upside, analysts plainly believe DXP Enterprises is more favorable than Capstone Therapeutics.

Summary

DXP Enterprises beats Capstone Therapeutics on 13 of the 14 factors compared between the two stocks.

About Capstone Therapeutics

Capstone Therapeutics Corporation was a biotechnology company focused on developing peptide-based therapeutics for tissue repair and regenerative medicine. Its research programs centered on synthetic peptides designed to influence healing and recovery in areas such as bone, soft tissue and cardiovascular injury. The company’s principal historical programs included Chrysalin (TP508), an experimental peptide derived from a portion of the human thrombin protein that was investigated for applications in bone and tissue healing, and AZX100, a peptide-based candidate studied for its potential to reduce fibrosis and postsurgical scarring.

About DXP Enterprises

DXP Enterprises, Inc. is a distributor of industrial products and provider of related services. It supplies maintenance, repair and operating products, including bearings, power-transmission components, safety equipment and other industrial supplies to customers in a range of industries. The company also provides pump and rotating-equipment services, such as pump repair and packaged pumping systems, as well as supply-chain services that support customers’ procurement and inventory-management needs.